CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting. Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASCO 2020.
[embedyt] https://www.youtube.com/watch?v=sjmhabf05sk&width=550&height=309&iv_load_policy=3¢ervid=1&rel=0[/embedyt]
You can see the ASCO20 virtual agenda and abstracts here. All presentations will be available on the ASCO20 website for a period of 180-days.
